Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-11-27
2004-09-21
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S343000
Reexamination Certificate
active
06794388
ABSTRACT:
The present invention is directed to the succinate salts of 5,8,14-triazatetracyclo[10.3.1.0
2,11
.0
4,9
]-hexadeca-2(11),3,5,7,9-pentaene
and pharmaceutical compositions thereof. The succinate salts can take an anhydrous form or a hydrated form.
The compound, 5,8,14-triazatetracyclo[10.3.1.0
2,11
.0
4,9
]-hexadeca-2(11),3,5,7,9-pentaene, binds to neuronal nicotinic acetylcholine specific receptor sites and is useful in modulating cholinergic function. This compound is useful in the treatment of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular, palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.
The succinate salts of this invention may also be used in a pharmaceutical composition in combination with an antidepressant such as, for example, a tricyclic antidepressant or a serotonin reuptake inhibiting antidepressant (SRI), in order to treat both the cognitive decline and depression associated with AD, PD, stroke, Huntington's chorea or traumatic brain injury (TBI); in combination with muscarinic agonists in order to stimulate both central muscarinic and nicotinic receptors for the treatment, for example, of ALS, cognitive dysfunction, age-related cognitive decline, AD, PD, stroke, Huntington's chorea and TBI; in combination with neurotrophic factors such as NGF in order to maximize cholinergic enhancement for the treatment, for example, of ALS, cognitive dysfunction, age-related cognitive decline, AD, PD stroke, Huntington's chorea and TBI; or in combination with agents that slow or arrest AD such as cognition enhancers, amyloid aggregation inhibitors, secretase inhibitors, tau kinase inhibitors, neuronal anti-inflammatory agents and estrogen-like therapy.
Compounds that bind to neuronal nicotinic receptor sites, including 5,8,14-triazatetracyclo[10.3.1.0
2,11
.0
4,9
]-hexadeca-2(11),3,5,7,9-pentaene, and its hydrochloride salt, are referred to in WO 99/35131, published Jul. 15, 1999 (corresponding to U.S. Ser. Nos. 09/402,010, filed Sep. 28, 1999 and 09/514,002, filed Feb. 25, 2000). The foregoing applications, owned in common with the present application and incorporated herein by reference in their entirety, generically recite pharmaceutically acceptable acid addition salts for the compounds referred to therein.
The succinate salts of the present invention exhibits properties, including those of solid-state stability and compatibility with certain drug product formulation excipients, that render it preferable among known salts of 5,8,14-triazatetracyclo[10.3.1.0
2,11
.0
4,9
]-hexadeca-2(11),3,5,7,9-pentaene. Further, the succinate salt formation is an extremely efficient means of purifying 5,8,14-triazatetracyclo[10.3.1.0
2,11
.0
4,9
]-hexadeca-2(11),3,5,7,9-pentaene.
REFERENCES:
patent: WO9935131 (1999-07-01), None
patent: 1157726 (2001-11-01), None
Quallich George J.
Wint Lewin T.
Ginsburg P. H.
Joran A. D.
Kifle Bruck
Pfizer Inc.
Richardson P. C.
LandOfFree
Succinic acid salts of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Succinic acid salts of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Succinic acid salts of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3238273